The overarching goal of the Clinical Core is to characterize the behavioral, cognitive, motor, neuroimaging, proteomic and genetic features of ADRC subjects in novel, multidisciplinary ways, and facilitate enrollment of subjects in studies of normal and abnormal aging.
The specific aims of the Clinical Core are to 1) Recruit, evaluate, and longitudinally follow cohorts of normal elderly (n=200), patients with mild cognitive impairment (MCI;n=120), mild AD (n=120), frontotemporal dementia-spectrum (n=120), and Creutzfeldt-Jakob disease (CJD;n=10);2) Work with the Education Core to recruit, evaluate, and longitudinally follow 120 Chinese- American patients and controls;3) Provide clinical data and well characterized subjects for research on aging and neurodegenerative disease;and 4) Work closely with the other UCSF ADRC Cores to provide integrated and comprehensively characterized subjects for research, including biological samples for genomic and proteomic research, structural and functional neuroimaging, and amyloid biomarkers. All subjects will be evaluated using the UDS plus several neurological, cognitive, and personality measures specific to UCSF to better understand the heterogeneity of and overlap between dementias, improve our ability to capture the very earliest signs of neurodegeneration, study the transition from normal aging to MCI, and elucidate underlying neural networks and mechanisms..
|Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21|
|Barton, Cynthia; Ketelle, Robin; Merrilees, Jennifer et al. (2016) Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias. Curr Neurol Neurosci Rep 16:14|
|Rabinovici, Gil D (2016) Amyloid biomarkers: pushing the limits of early detection. Brain 139:1008-10|
|Voyle, N; Kim, M; Proitsi, P et al. (2016) Blood metabolite markers of neocortical amyloid-Î² burden: discovery and enrichment using candidate proteins. Transl Psychiatry 6:e719|
|Schott, Jonathan M; Crutch, Sebastian J; Carrasquillo, Minerva M et al. (2016) Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement 12:862-71|
|Yokoyama, Jennifer S; Desikan, Rahul S (2016) Association of Alzheimer Disease Susceptibility Variants and Gene Expression in the Human Brain-Reply. JAMA Neurol 73:1255|
|LoBue, Christian; Denney, David; Hynan, Linda S et al. (2016) Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis. J Alzheimers Dis 51:727-36|
|Mair, Waltraud; Muntel, Jan; Tepper, Katharina et al. (2016) FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. Anal Chem 88:3704-14|
|Oh, Hwamee; Madison, Cindee; Baker, Suzanne et al. (2016) Dynamic relationships between age, amyloid-Î² deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. Brain 139:2275-89|
|Guo, Christine C; Sturm, Virginia E; Zhou, Juan et al. (2016) Dominant hemisphere lateralization of cortical parasympathetic control as revealed by frontotemporal dementia. Proc Natl Acad Sci U S A 113:E2430-9|
Showing the most recent 10 out of 390 publications